TB-500 10 mg

Compound profile

TB-500: compound profile, literature landscape and handling notes

Where TB-500 came from

The parent molecule has an older and more respectable history than the product name suggests. Beta-thymosins were first pulled out of thymic tissue extracts during the era when the thymus was being searched for circulating hormonal factors, and thymosin beta-4 took its name from that search and from its position in the fractionation, not from anything it was later shown to do. The hormonal framing did not survive. Thymosin beta-4 turned out to be an abundant, largely cytoplasmic polypeptide present across many cell types rather than a thymus-restricted signaling molecule, and its established function is a binding function inside the cell. The name is therefore a historical artifact, which is worth knowing because it is the first of several ways this compound invites people to believe something about it that is not true.

TB-500 is a separate thing again. It is a commercial designation rather than a name from the primary literature: the peptide sold under it is a short synthetic sequence built around the actin-binding motif of the parent protein, and the designation circulated in vendor and veterinary contexts well before it appeared anywhere in a peer-reviewed methods section. Searching the literature for the string TB-500 returns comparatively little; searching for thymosin beta-4 returns a substantial corpus about a 43-residue protein. Vendors and secondary sources bridge that gap by treating the two as synonyms, and the bridge does not hold.

The practical consequence for anyone building a citation list is severe and specific. If a claim attached to TB-500 traces back to a paper, the first question is which molecule that paper actually used. In the overwhelming majority of cases it is the full-length protein, often recombinant, often at concentrations and in intracellular contexts that have no obvious mapping onto a synthetic heptapeptide-scale fragment applied from outside a cell. That is not a reason to discard the parent literature. It is a reason to cite it as what it is, and to stop describing the fragment as though those results were generated with it.

Reading the structure of TB-500

The sequence, formula and mass for this listing are printed in the specification table further down this page, and the first thing to do is read them against the parent protein rather than in isolation. The parent is 43 residues. What is in the vial is a small fraction of that, organized around one motif.

That motif is LKKTETQ, a heptapeptide that sits in the central region of thymosin beta-4 and forms part of the surface that contacts actin. Calling something a binding motif fragment means a particular thing: the parent protein has a contact surface made of several discontinuous elements, one of those elements is a short contiguous stretch of sequence, and that stretch has been excised and made on its own. A fragment of this kind can retain a version of one function of the parent, because the local chemistry that made those seven residues part of the interface is still present, while losing everything the parent achieved through the rest of its chain. In thymosin beta-4 the actin interface is not the motif alone; an amphipathic helix toward the N-terminus and residues toward the C-terminus both participate. Removing them does not abolish contact, but it removes avidity, orientation and the conformational context that the intact chain provides. A fragment should be expected to be a much weaker binder than its parent, and to be a poorer mimic the more of the interface it leaves behind.

Everything else about the structure is defined by absence. There is no cysteine, so no disulfide bond, no oxidative folding step and no isomer separation during purification. There is essentially no aromatic character, which has consequences for detection that are dealt with in the analytical notes below. There is no fatty-acid conjugation, so none of the albumin-binding, surfactant behavior that dominates the acylated peptides elsewhere in this catalog applies here at all. The composition is instead dominated by charge: two lysine side chains carrying positive charge at neutral pH, a glutamate carrying negative charge, hydroxyl-bearing threonines and a carboxamide-bearing glutamine. That combination is what makes the molecule very hydrophilic and it is the origin of both its good solution behavior and its awkward chromatography.

One structural feature is genuinely contested rather than merely absent, and it concerns the N-terminus. Native thymosin beta-4 is N-terminally acetylated. A synthetic fragment usually is not, unless a supplier states otherwise. That is a real chemical difference, not a formality, and it is addressed separately below because it is so rarely stated on a label.

The target and the pathway in more detail

The canonical biochemistry of thymosin beta-4 is sequestration of monomeric actin. In many cell types it is the major G-actin-binding protein by abundance, and its function is to hold a large reservoir of unpolymerized actin monomers in a form that cannot spontaneously add to filament ends. That buffering is what allows a cell to keep a high concentration of assembly-competent subunits on hand and to release them locally and quickly when filament growth is required. Through that mechanism the protein participates in cytoskeletal remodeling, in the leading-edge dynamics of migrating cells, and in every process downstream of those, which is a long list.

The first thing to be precise about is the kind of interaction this is. It is a protein-protein interaction with a cytoplasmic partner, not a ligand binding a receptor. There is no signal transduction cascade attached to it, no second messenger, no G protein and no kinase recruited by the binding event itself. Actin sequestration is stoichiometric buffering chemistry, and the appropriate mental model is a binding equilibrium with a large intracellular pool, not an occupancy-response curve at a cell surface.

The second thing to be precise about is that no cell-surface receptor for TB-500 has been established. This matters more for the fragment than for the parent, because the parent's known function is intracellular and the fragment, in nearly every experiment done with it, is applied to the outside of cells. How a small, highly charged, very hydrophilic peptide would reach a cytoplasmic actin pool is not answered anywhere in the accessible literature, and proposals in that direction are inference rather than measurement.

Downstream of the core biochemistry, the literature on the parent protein invokes several further themes: promotion of angiogenic behavior in endothelial preparations, effects on the actin cytoskeleton in migrating cell populations, and a set of reported anti-inflammatory readouts in tissue models. Each is reported for thymosin beta-4. Each is routinely reattributed to TB-500. The honest position is that G-actin sequestration is established biochemistry of the 43-residue protein, that migration and angiogenic readouts are reported effects of that protein in defined systems, and that what the isolated motif fragment does when applied extracellularly is a separate and much less answered question.

What the published literature on TB-500 actually measures

The published record splits cleanly along the fragment-versus-protein line, and sorting a reference list by which molecule was actually used is the highest-value hour anyone will spend on this compound.

The largest and best-developed body of work uses full-length thymosin beta-4. It includes the structural and biochemical characterization of the actin interaction, expression and localization work across tissues, and a substantial preclinical literature in injury and repair models. Cardiac work using the intact protein in rodent models of ischemic injury is among the most cited of these, and ophthalmic work on corneal surface repair advanced far enough to reach clinical-stage development, which makes the parent protein one of the few molecules discussed anywhere near this catalog to have been formally evaluated in people. None of that development concerned a synthetic heptapeptide-scale fragment, and none of it should be described as TB-500 data.

The second body of work is cell-level and mechanistic: migration assays, scratch and wound-closure preparations, transwell and chemotaxis assays, tube-formation assays in endothelial culture, and actin-polymerization measurements in vitro. This is where fragment work does appear, because a short synthetic peptide is cheap to include as an arm in a culture experiment. It is also where the weakest inferences originate, since migration and closure endpoints in culture are sensitive to proliferation, to medium composition, to serum lot and to the mechanics of how the monolayer was scratched, and they are frequently reported without the controls that would separate migration from proliferation.

The third body is rodent in vivo injury and repair work, which is heavily weighted toward the parent protein and toward soft-tissue, dermal, corneal and cardiac models. The readouts are the familiar ones: histological scoring, vessel density counts, functional indices and immunostaining for migration and angiogenesis markers.

A fourth category is worth naming only so that it can be excluded. Equine and other veterinary contexts account for a noticeable share of the material circulating under the TB-500 name, and much of that material is regulatory documentation, testing-control notices and trade writing rather than experimental literature. It establishes that the designation was in use and that analytical methods were developed to detect it. It does not characterize the molecule pharmacologically, and it should not be cited as though it did.

What is almost entirely absent is controlled human work on the fragment itself. There is no body of evaluable clinical data generated with a synthetic motif fragment, which is a statement about absence rather than about failure. That vacuum is frequently filled by borrowing the parent protein's preclinical and clinical-stage record, which is the central citation error described in the section that follows.

Where the TB-500 literature is thin or frequently misread

This is the section that matters, because the problems here are problems of identity and attribution rather than of experimental technique.

The first and largest is the citation problem already named. A very substantial fraction of the claims circulating under the name TB-500 are supported, if they are supported at all, by studies performed with the intact 43-residue protein. That includes essentially all of the cardiac work, the corneal and clinical-stage development record, and much of the angiogenesis literature. Substituting a fragment for the protein in a citation is not a small approximation. It changes the molecule, the binding avidity, the compartment in which the molecule was present, and in most cases the mode of delivery in the original experiment. Any reference list for this compound should carry, for each entry, an explicit note of which species was used.

The second is that TB-500 is a vendor designation rather than a defined pharmaceutical entity. There is no monograph, no pharmacopeial specification and no originator program that fixes what the name denotes. In practice the label is applied to fragments of somewhat different lengths, with different flanking residues around the core motif, and occasionally to preparations that are described as the full-length protein. Two vials from two suppliers labeled TB-500 may not be the same molecule. This is not a hypothetical concern about quality; it is a concern about identity, and it means the sequence as stated in the specification record, confirmed analytically, is the only thing that defines what is being worked with.

The third is acetylation. Native thymosin beta-4 carries an N-terminal acetyl group. A synthetic fragment ordinarily does not. That difference removes a free alpha-amino group and the positive charge that goes with it, changes susceptibility to aminopeptidase trimming, shifts chromatographic retention slightly and shifts mass by a defined amount. It is a real chemical distinction between the acetylated and non-acetylated forms, and it is almost never stated in secondary discussion of this compound. A related point is that the parent protein is also the source of an entirely different and separately studied fragment derived from its N-terminal region, which has its own literature and is not this molecule.

The fourth is the routine over-extrapolation of migration-assay results. Faster closure of a scratch in a monolayer is a statement about a monolayer. It is not evidence of tissue repair, it does not distinguish migration from proliferation without a proliferation-blocked control, and it is one of the most environmentally sensitive assays in common use. The distance between that measurement and the claims made on its behalf is the largest in this compound's literature.

How TB-500 behaves in solution

By the standards of this catalog TB-500 is an unusually cooperative molecule in solution, and the reason is compositional. A sequence dominated by charged and hydroxyl-bearing residues, with no lipid chain and effectively no hydrophobic core, is about as water-friendly as a peptide gets. It dissolves readily in water and in ordinary aqueous buffers without an organic co-solvent, without a pH excursion and without the sonication or gentle warming that a stubborn hydrophobic sequence sometimes needs. There is no surfactant character, no concentration-dependent micellization and no albumin-binding tail to complicate a matrix. Solutions are clear and colorless, and they stay that way.

The lysine content deserves separate attention because it drives the handling behavior. At neutral pH the molecule carries net positive charge, which means it will adsorb to anionic surfaces through straightforward electrostatics: exposed silanols on glass, negatively charged sites on some plastics and filter membranes, and any ion-exchange character in a frit or a syringe filter. This is a different adsorption mechanism from the hydrophobic partitioning that costs material from acylated peptides, and it responds to different countermeasures. Raising ionic strength competes with it; low-binding or silanized labware helps; passing a dilute solution through a charged filter membrane is an efficient way to lose a fraction of it without any visible sign.

The other point worth making plainly is that high solubility is not high stability, and the two are constantly conflated. A molecule that dissolves easily can still hydrolyze, deamidate or be trimmed by contaminating protease activity, and none of those show up as turbidity. The slow deamidation of side-chain carboxamide groups is the chemistry to keep in view here, and its most awkward property is that the resulting mass change is very small relative to the parent, which makes it easy to miss on a low-resolution measurement. An unprotected N-terminus, if the material is not acetylated, is also an entry point for aminopeptidase activity in any biological matrix. Freeze-thaw cycling is less punishing for a small hydrophilic peptide than for an aggregation-prone amphiphile, but single-use aliquots remain the sensible pattern, and an aqueous solution held unpreserved at room temperature should be treated as a microbial growth question before it is treated as a chemistry question. Lyophilized material of this composition is hygroscopic and often forms a very light, low-density cake that is easy to lose to static or to airflow.

Analytical notes specific to TB-500

Two properties of this sequence make it awkward to analyze, and both are consequences of the composition described above.

The first is detection. There is no tryptophan and effectively no aromatic character at all, so absorbance at 280 nm is not merely weak but unusable; a 280 nm trace of this peptide is a flat line and cannot be used to quantify anything. Quantitation in practice falls to low-ultraviolet detection around 214 nm, where the response comes from the amide bond itself. That works, with two known caveats. Response scales roughly with the number of peptide bonds, so short truncation and deletion impurities under-respond relative to the full-length species and area-percent purity systematically understates them on a molar basis. And 214 nm is a region where mobile-phase components, additives and dissolved impurities absorb, so baseline quality and mobile-phase purity affect the number more than they would at 280 nm. A second problem is retention rather than detection: a very hydrophilic, charged peptide is poorly retained on conventional reversed-phase stationary phases and tends to elute near the void, where it co-elutes with salts and small polar contaminants. Ion-pairing additives, a polar-embedded or aqueous-compatible stationary phase, or a hydrophilic-interaction separation are the usual ways around it, and a method developed for a hydrophobic peptide will not transfer.

The second is the peptide-mapping problem. Trypsin cleaves after lysine and arginine residues, and this sequence is lysine-rich in a very short chain. A tryptic digest therefore produces fragments of one, two and three residues, which are too small to be informative, often too polar to retain on the column, and in some cases indistinguishable from digest background. Peptide mapping, which is the default confirmatory approach for larger molecules, adds very little here. Tandem mass spectrometry on the intact molecule is the more useful route, because a fragment ion series across a chain this short can establish the actual residue order.

That distinction matters because an intact-mass measurement alone is weakly discriminating for a sequence like this one. Any permutation of the same residues has the same mass, leucine and isoleucine are isobaric and cannot be separated by mass at all, and lysine and glutamine are identical at nominal mass and differ only by a fraction of a unit, which a low-resolution instrument will not resolve. A certificate reporting an observed mass consistent with the expected value has excluded gross errors and very little else. Confirming that the material in the vial is the intended fragment rather than a close sequence variant requires sequence-level evidence, and where the acetylation state matters it requires a measurement that speaks to the N-terminus specifically.

Compounds researchers confuse with TB-500

Questions specific to TB-500